Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap

Part of paid clinical trials in Lakewood, California.

Sponsor
Gelb, Arthur F., M.D.
Study ID
NCT03263130
Status
Recruiting

Conditions

  • COPD, Emphysema, Asthma COPD Overlap
  • Emphysema

Eligibility Criteria

Sex
ALL
Age
30 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap — OTHER

Study Details

The purpose of this cross-sectional, observational study is to evaluate the site and mechanism(s) for expiratory airflow limitation in chronic, treated, current or former smokers (\>15 pack years) with COPD, Emphysema, and Asthma-COPD Overlap with mild to severe expiratory airflow limitation. Treatment may include short and long acting inhaled beta2agonists, short and long acting inhaled muscarinic receptor antagonists, inhaled and or oral corticosteroid, oral antibiotic, supplemental oxygen, and PDE type 4 inhibitor. In some cases, the patient may have had a history of asthma preceding the development of COPD (Asthma COPD Overlap).

Key Dates

Start date
Jan 1, 2017
Status verified
Oct 2023
Primary completion
Jan 1, 2027
Completion
Dec 1, 2027

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: COPD, Emphysema, Asthma-COPD Overlap
    Based on clinical, pathologic, laboratory, physiologic and radiologic differences, patient groups can be described.

Primary Outcome Measure

Site and Mechanism(s) of Expiratory Airflow Limitation [ Time Frame: 4 years ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Arthur F Gelb MDLakewoodCalifornia90712
Arthur F Gelb, MD
562-633-2204
Christine Fraser
562-633-2204
Arthur F Gelb, MD (PRINCIPAL_INVESTIGATOR)
Arthur F Gelb MDLakewoodCalifornia90712
Arthur F Gelb, MD
562-633-2204
Christine Fraser
562-633-2204

Find similar trials in Lakewood, CA

By condition

Related Studies